Current worldwide clinical trials on COVID-19
Analysis of Clinical Trial Data
Using dimensions.ai service and simple NLP scripts, the following figures show the distribution of COVID-19 clinical trials around the world and the different types of trials. These statistics are synchronized with each update from the figshare table.
Figures Last Updated: September 17, 2020
Download links for all three types of clinical trials are listed below.
Similarily, using the same data, a preliminary small molecule treatment list with clinical trial counts was automatically generated using relevant key words. This list is only an estimate and will be updated daily. The list for this figure is available for download in the Treatment list link above.
Selected Drug information of current ongoing clinical studies on COVID-19
The information below is collected from recent research articles, news articles, or clinical reports of COVID-19 studies contributed from various research groups worldwide. The source links or full article download are provided to facilitate your own investigation and research on these molecules.
|Drug Name||Structure||MoA||Indication||DrugBank URL||Anti-2019-nCoV Evidence||Reference|
|Remdesivir||RNA polymerase inhibitor||Anti-Ebola passed Phase III, COVID-19 Phase III||DB14761||In Vitro Assay, Clinical report, Clinical trial||7; 8; 14; 15; 16|
|Lopinavir||Protease inhibitor||Anti-HIV approved, COVID-19||DB01601||Clinical Trial||1; 2; 3; 4; 5; 6|
|Ritonavir||Protease inhibitor||Anti-HIV approved, COVID-19||DB00503||Clinical Trial||1; 2; 3; 4; 5; 6|
|Emtricitabine||nucleoside reverse transcriptase inhibitor||Anti-HIV approved, anti-HBV||DB00879||Clinical Trial||2|
|Tenofovir||nucleoside reverse transcriptase inhibitor||Anti-HIV Phase III, anti-HBV||DB14126||Clinical Trial||2|
|Ribavirin||viral mRNA and protein synthesis inhibitor||Anti-HCV, Anti-HBV, Anti-SARS, Anti-influenza, COVID-19||DB00811||Clinical Trial||5|
|Umifenovir||Influenza approved, COVID-19 Phase 4||DB13609||Clinical trial||9; 22|
|Ruxolitinib||KInase inhibitor||COVID-19 Phase 0||DB08877||Clinical Trial||28|
|Favipiravir||RNA polymerase inhibitor||Anti-influenza approved, anti-Ebola Phase II||DB12466||Clinical Trial||10; 18|
|Darunavir||Protease inhibitor||Anti-HIV approved||DB01264||Clinical Trial||11|
|Cobicistat||Anti-HIV approved||DB09065||Clinical trial||11|
|Methylprednisolone||Corticosteroid||COVID-19 Phase II, allergic asthma and rheumatic disorders approved||DB00959||Clinical Trial||12; 13|
|Baloxavir marboxil||Polymerase inhibitor||anti-influenza approved||DB13997||Clinical Trial||21|
|Oseltamivir||Neuraminidase inhibitor; Sialidase inhibitor||anti-influenza approved, COVID-19 Phase III||DB00198||Clinical Trial||22|
|IFN alpha-1b||Immunomodulation||Interferon||Clinical trial||5; 6|
|Danoprevir||Protease inhibitor||anti-HCV Phase III, COVID-19 Phase 4||DB11779||Clinical Trial||23|
|Peginterferon alfa-2a||Immunomodulation||HCV approved, COVID-19 Phase 4||DB00008||Clinical trial||23|
|Chloroquine||Antimalarial approved, anti-HIV phase III, anti-HCV, COVID-19 Phase 4||DB14761||In Vitro Assay, Clinical trial||7; 15; 17|
|Azvudine||anti-HIV approved||PubChem 24769759||Clinical trial||19; 20|
|Dipyridamole||Adenosine deaminase and phosphodiesterase inhibitor||COVID-19 Phase 4; Phase 4 completed for stroke prevention; Phase 4 completed for coronary arteriosclerosis||DB00975||Clinical Trial||24; 25|
|Thalidomide||COVID-19 Phase 2; Phase 3 completed for cancers||DB01041||Clinical Trial||26|
|Fingolimod||COVID-19 Phase 2; Phase 4 completed for Multiple Sclerosis||DB08868||Clinical Trial||27|
|Triazavirin||RNA synthesis inhibitor||COVID-19 Phase 3||DB15622||Clinical Trial||29|
|Tranilast||Hematopoietic prostaglandin D synthase inhibitor||Phase 4 completed for Conjunctivitis; COVID-19 Phase 4||DB07615||Clinical Trial||30|
|Acetylcysteine||Mucolytic agent||Phase 4 completed for Drug Overdose, AMI, Bipolar disorder, lung diseases; COVID-19 Phase 4||DB06151||Clinical Trial||31|
|Ebastine||H1 inhibitor||Phase 4 completed for IBS, urticaria; COVID-19 Phase 4||DB11742||Clinical Trial||32|
|Losartan||Angiotensin II receptor blocker||Phase 4 completed for high blood pressure, hypertension, diabetes mellitus, kidney diseases, stroke; COVID-19 Phase 2||DB00678||Clinical Trial||33|
|Pirfenidone||Collagen synthesis inhibitor, Profibrotic cytokine down-regulator||Phase 4 completed for IPF; Phase 3 completed for DFU; COVID-19 Phase 0||DB04951||Clinical Trial||34|
|Camostat||COVID-19 Phase I||DB13737||Clinical Trial||35|
Last update: October 15, 2020
Your feedback is highly appreciated.